1. Home
  2. IOVA vs SEMR Comparison

IOVA vs SEMR Comparison

Compare IOVA & SEMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • SEMR
  • Stock Information
  • Founded
  • IOVA 2007
  • SEMR 2008
  • Country
  • IOVA United States
  • SEMR United States
  • Employees
  • IOVA N/A
  • SEMR N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • SEMR EDP Services
  • Sector
  • IOVA Health Care
  • SEMR Technology
  • Exchange
  • IOVA Nasdaq
  • SEMR Nasdaq
  • Market Cap
  • IOVA 975.1M
  • SEMR 1.2B
  • IPO Year
  • IOVA N/A
  • SEMR 2021
  • Fundamental
  • Price
  • IOVA $2.38
  • SEMR $7.57
  • Analyst Decision
  • IOVA Buy
  • SEMR Buy
  • Analyst Count
  • IOVA 11
  • SEMR 8
  • Target Price
  • IOVA $11.90
  • SEMR $14.88
  • AVG Volume (30 Days)
  • IOVA 11.2M
  • SEMR 1.2M
  • Earning Date
  • IOVA 11-06-2025
  • SEMR 11-06-2025
  • Dividend Yield
  • IOVA N/A
  • SEMR N/A
  • EPS Growth
  • IOVA N/A
  • SEMR N/A
  • EPS
  • IOVA N/A
  • SEMR N/A
  • Revenue
  • IOVA $241,525,000.00
  • SEMR $413,962,000.00
  • Revenue This Year
  • IOVA $67.40
  • SEMR $20.28
  • Revenue Next Year
  • IOVA $56.32
  • SEMR $16.41
  • P/E Ratio
  • IOVA N/A
  • SEMR N/A
  • Revenue Growth
  • IOVA 636.99
  • SEMR 22.16
  • 52 Week Low
  • IOVA $1.64
  • SEMR $7.01
  • 52 Week High
  • IOVA $12.51
  • SEMR $18.74
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 49.08
  • SEMR 43.24
  • Support Level
  • IOVA $2.27
  • SEMR $7.32
  • Resistance Level
  • IOVA $2.46
  • SEMR $7.90
  • Average True Range (ATR)
  • IOVA 0.14
  • SEMR 0.22
  • MACD
  • IOVA 0.00
  • SEMR 0.03
  • Stochastic Oscillator
  • IOVA 49.09
  • SEMR 33.11

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About SEMR SEMrush Holdings Inc.

SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.

Share on Social Networks: